Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy
SourceClinical and Translational Oncology
Google Scholar check
MetadataShow full item record
Although modern social structure and medical advances have led to the increasing number of women childbearing in older age, cancer remains a rare diagnosis during pregnancy. There is little given information throughout the literature concerning gestation associated with the coexistence of gastrointestinal stromal tumor (GIST). In this review, we present 12 reported cases of GIST during pregnancy and we discuss the maternal and fetal outcome, as well as the therapeutic plan that was followed in each situation. From the collected data, 8 out of 12 cases had an uneventful outcome of their fetus. In 11 out of 12 cases surgical excision of the tumor was the treatment of choice, while seven women were treated with imatinib. Two of them were already on imatinib therapy during conception due to preexisting GIST diagnosis. Surgery remains the gold standard for the treatment of local or resectable GIST, while published data concerning the use of imatinib during pregnancy indicate that teratogenicity or fetal loss might be induced, especially if given during the first trimester of pregnancy. GIST during gestational period is a rare tumor in which a multidisciplinary approach should be designed, taking always into consideration that it has a favorable outcome on targeted treatment. © 2015, Federación de Sociedades Españolas de Oncología (FESEO).
Showing items related by title, author, creator and subject.
Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors Azim, Hatem A.; Pavlidis, Nicholas; Peccatori, Fedro A. (2010)Managing pregnant patients with hematological tumors pose even more conflicts compared to solid tumors. Unlike the majority of solid tumors, hematological malignancies are potentially curable; hence it is important to ...
Whole-genome fetal and maternal DNA methylation analysis using MeDIP-NGS for the identification of differentially methylated regions Keravnou, Anna; Ioannides, Marios; Tsangaras, Kyriakos; Loizides, Charalambos; Hadjidaniel, Michael D.; Papageorgiou, Elisavet A.; Kyriakou, Skevi; Antoniou, Pavlos; Mina, Petros; Achilleos, Achilleas P.; Neofytou, Maria C.; Kypri, Elena; Sismani, Carolina; Koumbaris, George L.; Patsalis, Philippos C. (2016)DNA methylation is an epigenetic marker that has been shown to vary significantly across different tissues. Taking advantage of the methylation differences between placenta-derived cell-free DNA and maternal blood, several ...
The pregnant mother with breast cancer: Diagnostic and therapeutic management Pavlidis, Nicholas; Pentheroudakis, George (2005)This review describes the epidemiology, pathology, clinical picture and therapeutic management of pregnant women with breast cancer. In addition, it covers other important issues like the safety of both diagnostic and ...